Physician profile
Peter B Wade
NPI 1275636326
$302,157.09
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205K · 2020: $54K · 2021: $44K · 2022: $70.68.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $110,562.51 | 2019-2021 | |
| Genentech USA, INC. | $57,875.18 | 2019-2021 | |
| Celgene Corporation | $44,127.30 | 2019-2021 | |
| Emd Serono, INC. | $34,413.29 | 2019-2021 | |
| Genzyme Corporation | $27,001.21 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $7,754.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $7,627.38 | 2019-2021 | |
| Tg Therapeutics, INC. | $4,942.16 | 2021 | |
| Mallinckrodt Hospital Products INC. | $4,210.96 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $3,311.87 | 2020-2021 | |
| Genentech, INC. | $247.17 | 2019-2022 | |
| Acorda Therapeutics, INC | $30.64 | 2019 | |
| Merz North America, INC. | $22.91 | 2020 | |
| Abbvie INC. | $17.32 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.25 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.